Information Provided By:
Fly News Breaks for January 10, 2020
EXAS
Jan 10, 2020 | 08:05 EDT
BTIG analyst Amanda Murphy assumed coverage of Exact Sciences with a Buy rating and $127 price target. In a research note to investors, Murphy says she still sees meaningful room for growth in utilization of CRC screening. The analyst says market penetration of Cologuard is currently around 5%, and assumes Exact can get to 40% market penetration by 2030. Additionally, she says the acquisition of Genomic Health adds a key sales channel in oncology.
News For EXAS From the Last 2 Days
There are no results for your query EXAS